Core Insights - The research published in "Nature Aging" reveals the critical role of the "lipid metabolism-microglial activation-neuroinflammation" axis in Alzheimer's disease, identifying MFE-2 as a novel therapeutic target for drug development [1][2] - CKBA, a small molecule candidate derived from natural products, shows potential in targeting immune metabolism and is being developed for Alzheimer's treatment [1][2] Company Developments - CKBA demonstrates effective blood-brain barrier penetration, good pharmacokinetic properties, and multiple therapeutic effects in Alzheimer's model mice, including cognitive improvement and reduced neuroinflammation [2] - The company is advancing CKBA's development for both vitiligo (Phase III) and rosacea (Phase II/III) while accelerating its innovative drug development for Alzheimer's disease, potentially benefiting millions of patients [2] Research Contributions - The study highlights a key target in the early metabolic-inflammatory coupling pathway of Alzheimer's disease and provides a basis for the design of targeted small molecules derived from natural products [2] - The research marks a significant breakthrough for the team in the field of Alzheimer's intervention, showcasing a complete chain from mechanism research to translational application [2]
泰恩康创新药CKBA治疗阿尔兹海默症的创新研究成果登上国际顶刊《Nature Aging》